Illumina Ret. on equity

What is the Ret. on equity of Illumina?

The Ret. on equity of Illumina, Inc. is -42.80%

What is the definition of Ret. on equity?

Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.

ttm (trailing twelve months)

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

What does Illumina do?

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.

Companies with ret. on equity similar to Illumina

Bossini International has Ret. on equity of -42.92%
Bharat Road Network has Ret. on equity of -42.90%
Arcus Biosciences Inc has Ret. on equity of -42.86%
Monarch Mining has Ret. on equity of -42.83%
Shandong Molong Petroleum Machinery has Ret. on equity of -42.82%
Galiano Gold has Ret. on equity of -42.81%
Illumina has Ret. on equity of -42.80%
Hi-Level Technology has Ret. on equity of -42.80%
Vimy Resources has Ret. on equity of -42.78%
Vimy Resources has Ret. on equity of -42.78%
Altan Rio Minerals has Ret. on equity of -42.76%
U.S. Gold Corp has Ret. on equity of -42.73%
E Automotive Inc has Ret. on equity of -42.72%